The Oncology Institute, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company rebranded itself, which affects how you identify and trade the stock going forward.
Debt increases company obligations and affects financial flexibility and future earnings available to shareholders.
These votes determine who oversees the company and whether shareholders accept management's compensation decisions.
Data breaches can lead to legal costs, reputation damage, and operational disruptions that hurt business value.
Quarterly earnings show whether the company is making money and growing, critical for investment decisions.
Detailed quarterly filings reveal balance sheet health, cash flow, and detailed business segment performance.
Investor presentations communicate company strategy and outlook, helping shareholders understand management's vision.
Stocky reads The Oncology Institute, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
The Oncology Institute, Inc.'s most recent tracked filing was a 8-K on 3 Aug 2026: Company changes name to Starling Oncology, trading symbol to STLN.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.